Streetbeat News

Regulatory

NWGL

Nature Wood Group Limited (NWGL) anticipates a 75% revenue growth in FY24, expecting to reach $45M, up from $25.4M in FY23. This growth is attributed to new EU regulations favoring sustainably sourced wood, a market where NWGL, with its focus on FSC certified operations, holds a competitive advantage. The company also plans to expand its carbon credit projects globally, leveraging high-margin opportunities while supporting sustainability.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 2:32 pm

QNRX

Quoin Pharmaceuticals shares surged following the FDA's approval to include teenage subjects in its Netherton Syndrome clinical trials.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 2:31 pm

EPOW

Sunrise New Energy Co., Ltd. (NASDAQ:EPOW) announced its 'High-Energy Fast Charging Lithium Battery Graphite Anode Project' received approval from Guizhou Province's Department of Science and Technology. This project, part of the 'Industrialization of Advanced Scientific and Technological Achievements' plan, aims to enhance energy density, charging efficiency, and cycling performance of lithium batteries. The approval will provide additional funding and support, positioning EPOW as a leader in high-end battery graphite anode materials.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 2:28 pm

BARK

BARK Inc. has successfully regained compliance with NYSE listing standards, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 2:02 pm

QTRX

Quanterix Corporation (NASDAQ:QTRX) announced its Simoa p-Tau 217 blood test for Alzheimer's Disease (AD) received Breakthrough Device designation from the U.S. FDA. This designation highlights the test's potential as a more effective, non-invasive diagnostic tool for AD, addressing an unmet medical need. The p-Tau 217 test, utilizing Quanterix's high-definition diagnostics and ultra-sensitive research products, is intended to aid in the diagnostic evaluation of AD by measuring p-Tau 217 concentration in plasma. This development is a significant step in advancing AD diagnostics and patient care.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 2:02 pm

IOVA

Iovance Biotherapeutics' stock is trading higher following the announcement that the FDA has lifted a partial clinical hold on the IOV-LUN-202 trial, which is investigating LN-145 TIL cell therapy for non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 1:53 pm

ENTX

Entera Bio Ltd. (NASDAQ:ENTX), a leader in orally delivered peptides, has regained compliance with NASDAQ's minimum bid price requirement for continued listing on The NASDAQ Capital Market. This was achieved by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days as of March 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 1:47 pm

AKRO

QNRX

SMCI

Akero Therapeutics released promising Week 96 results from its HARMONY Phase 2B study of Efruxifermin, Super Micro Computer is set to join the S&P 500 with a Neutral rating from Goldman Sachs, and Quoin Pharmaceuticals received FDA clearance for teen recruitment in Netherton Syndrome studies.

Portfolio Pulse from ryanfaloona@benzinga.com

March 04, 2024 | 1:47 pm

HYLN

Hyliion Holdings Corp. (NYSE:HYLN) has regained compliance with the NYSE's continued listing minimum price criteria and will be removed from the noncompliant issuers list. This comes after Hyliion's average closing price of its common shares exceeded the $1.00 threshold over a consecutive 30-trading-day period, resolving the previous deficiency.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 1:45 pm

AAPL

SPOT

Apple Inc. has been fined €1.8 billion ($1.95 billion) by the EU for antitrust violations, specifically for restricting Spotify and other music streaming services from informing users about alternative payment options outside its App Store. The fine, stemming from a 2019 Spotify complaint about Apple's 30% App Store fees, is intended as a deterrent. Apple plans to challenge the decision in court and is also seeking to settle another EU antitrust investigation related to its mobile payment systems.

Portfolio Pulse from Rounak Jain

March 04, 2024 | 1:32 pm